Preventative effects of selenium-enriched Bifidobacterium longum on irinotecan-induced small intestinal mucositis in mice.

Abstract

Intestinal mucositis is a frequent side effect in cancer patients who are treated with chemotherapy. There are no effective treatment strategies to date. To find a novel way to alleviate mucositis, the effects of selenium-enriched Bifidobacterium longum (Se-B. longum) in preventing irinotecan (CPT-11)-induced intestinal mucositis in a mouse model were investigated. We tested the ability of Se-B. longum (Se 0.6 mg/kg, 5×108 cfu/mice) to reduce small intestinal mucositis induced by CPT-11 (75 mg/kg, daily) injected intraperitoneally for four consecutive days in mice. Se-B. longum significantly decreased mortality induced by CPT-11 from 71.4% to 16.7%. CPT-11 induced body weight loss, which was alleviated by preventative and simultaneous administration of Se-B. longum. Se-B. longum significantly decreased the severity of diarrhoea from 11 to 4% compared to the CPT-11 group. Inflammation, including intestinal shortening and upregulation of tumour necrosis factor-α and interleukin-1β induced by CPT- 11, were prevented by Se-B. longum. Se-B. longum is effective in preventing small intestinal mucositis induced by CPT-11 and therefore has potential to be used clinically by cancer patients.

• Authors: Y Qiu, J Zhang, R Ji, Y Zhou, L Shao, D Chen, J Tan
• Journal: Beneficial microbes (Benef Microbes) Vol. 10 Issue 5 Pg. 569-577 (May 28 2019) ISSN: 1876-2891 [Electronic] Netherlands
• PMID: 30964326 (Publication Type: Journal Article)

Chemical References

• Antioxidants
• Irinotecan
• Selenium

Topics

• Animals
• Antioxidants (metabolism)
• Bifidobacterium longum (growth & development, metabolism)
• Disease Models, Animal
• Irinotecan (administration & dosage, toxicity)
• Mice
• Mucositis (chemically induced, pathology, prevention & control)
• Probiotics (administration & dosage)
• Selenium (metabolism)
• Survival Analysis
• Treatment Outcome